patients. The literature of the last few years offers convincing information that supports this opinion, both in patients with normal kidney function [1] and in haemodialysis patients [2] .
So we were not surprised to learn that a second treatment course with a higher RBV dose in one of the two patients that failed a sustained viral response in our pilot study was as yet effective.
At the time that the guidelines for our pilot study were settled and placed on the website of the Dutch Federation of Nephrology (NFN) only scarce information was available concerning the use of RBV in renal insufficiency. It was even considered to becontraindicated. Partly based on earlier experience [3] we were convinced that RBV could be used in a safe and possibly effective way if the dosage could be guided by plasma trough level determinations aiming at a so-called therapeutic range (1.5-2.5 µg/ml). This range was defined on the available experimental information at that moment but there was no firm proof of the clinical efficacy. To start a pilot study we had to be very careful and made a choice for a relative low dose.
To prevent serious haemolytic anaemia-the most important complication of RBV-a high dose of erythropoietin (Epo) is necessary in the treatment of dialysis patients. A dose of 30 000-40 000 IU/week was permitted in the studies of Rendina [2] and Bruchfeld [4] and also in our study, but the mean dose remained limited to 19 000 IU/week in the last one.
During the first 12 weeks of our study the RBV plasma level was often low despite small increases of the dose. Based on this experience we will advocate now a higher starting dose of 300 mg/day, preceded by a much more generous use of Epo.
Plasma level monitoring of RBV promotes safety and helps to guide the dosing of RBV.
Future results will possibly help to define an optimal therapeutic range. A higher RBV dose is necessary to achieve still better results and this needs further exploration.
We believe that our pilot study has contributed to the effective treatment of hepatitis C-infected vulnerable dialysis patients. 
New recommendations in the treatment of Gram-positive bacteraemia in dialysis patients
Sir, Professor Ponticelli timely reviewed a wealth of important, new information on the prevention and treatment of Grampositive bacteraemia in dialysis patients. Surprisingly, despite the title of his paper [1], he does not discuss a point of major clinical relevance, i.e. the optimal empirical antibiotic regimen in haemodialysis patients with suspected bacteraemia. It should be based on local epidemiology (country, unit) and characteristics of the individual patient (history of MRSA carriage, recent hospitalization in a high MRSA risk setting such as an ICU). The incidence of MRSA bacteraemia in our chronic haemodialysis patients was very low in 2007 (0.063 per 1000 patient-days) and the previous 5 years (L. Labriola, unpublished data), and such episodes were only observed in patients with a history of recent ICU stay. Therefore, whenever bacteraemia is suspected, we still use cefazolin alone at the end of each HD session as a first-line empirical therapeutic option. This simple, inexpensive regimen has proved both safe and effective against methicillin-sensitive Staphylococcus aureus (MSSA) in dialyzed patients, in our hands and that of others [2] . Only a history of recent hospitalization, particularly in the ICU, or recent infection by another agent than MSSA, triggers the empirical choice of vancomycin, alone or with a thirdgeneration cephalosporin or aminoglycoside. We acknowledge that the local epidemiology of S. aureus strains may differ greatly from country to country [3] or unit to unit but emphasize that our approach has the major advantage not to favour the indiscriminate use of last-resort anti-MRSA antibiotics, be it vancomycin or the newer, more expensive drugs reviewed by Ponticelli. Professor Ponticelli further cited a single study of an antibiotic-lock solution as an effective method to reduce catheter-related bacteraemia (CRB) [1] . As showed by our recent meta-analysis of eight randomized controlled trials, the use of antimicrobial lock solutions (ALS) reduced the incidence of CRB by about a factor 3 [4]. However, the incidence of CRB with an ALS was similar to rates in units not using ALS but with a low CRB incidence. Moreover, two included studies with a low baseline incidence of CRB did not show a significant reduction of CRB by the ALS [4] . On the other hand, some trials revealed a dramatic reduction of CRB simply after reinforcing hygienic precautions in catheter care (discussed in [4] ). In our unit, the incidence of CRB in 2007 was 0.23 per 1000 catheter-days, without using ALS.
Finally, the author did not mention thrombocytopenia as a side effect of vancomycin [1] . Recently, Von Drygalski et al. reported thrombocytopenia due to vancomycin-dependent antiplatelet antibodies in 34 patients. [5] . Thus thrombocytopenia should be considered as a potential side effect of vancomycin, like cutaneous reactions, neutropenia and hepatotoxicity.
